These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36445572)

  • 1. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
    Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
    Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
    J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
    Song Z; Su H; Zhang Y
    Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events.
    Ng TL; Smith DE; Mushtaq R; Patil T; Dimou A; Yang S; Liu Q; Li X; Zhou C; Jones RT; Tu MM; Yan F; Bowman IA; Liu SV; Newkirk S; Bauml J; Doebele RC; Aisner DL; Gao D; Ren S; Camidge DR
    J Thorac Oncol; 2019 Apr; 14(4):596-605. PubMed ID: 30543838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
    Deng H; Liu C; Zhang G; Wang X; Liu Y
    Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
    Wang HY; Wu SG; Lin YT; Chen CY; Shih JY
    ESMO Open; 2022 Dec; 7(6):100742. PubMed ID: 36493600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.
    Tarigopula A; Ramasubban G; Chandrashekar V; Govindasami P; Chandran C
    Cancer Rep (Hoboken); 2020 Dec; 3(6):e1288. PubMed ID: 32881404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
    [No Abstract]   [Full Text] [Related]  

  • 15. ALK and ROS1 rearrangement tested by ARMS-PCR in non-small-cell lung cancer patients via cytology specimens: The experience of Shanghai Pulmonary Hospital.
    Cao Z; Wu W; Zhang W; Li Z; Gao C; Huang Y; Zhang L
    Diagn Cytopathol; 2020 Jun; 48(6):524-530. PubMed ID: 32150350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.
    Dang AH; Tran VU; Tran TT; Thi Pham HA; Le DT; Nguyen L; Nguyen NV; Thi Nguyen TH; Nguyen CV; Le HT; Thi Nguyen ML; Le VT; Nguyen PH; Vo BT; Thi Dao HT; Nguyen LT; Van Nguyen TC; Bui QN; Nguyen LH; Nguyen NH; Thi Nguyen QT; Le TX; Do TT; Dinh KT; Do HN; Phan MD; Nguyen HN; Tran LS; Giang H
    Sci Rep; 2020 Feb; 10(1):2707. PubMed ID: 32066856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.
    Mitiushkina NV; Romanko AA; Preobrazhenskaya EV; Tiurin VI; Ermachenkova TI; Martianov AS; Mulkidjan RS; Sokolova TN; Kholmatov MM; Bizin IV; Ivantsov AO; Yatsuk OS; Zaitseva OA; Iyevleva AG; Kuligina ES; Imyanitov EN
    Cancer Med; 2022 Sep; 11(17):3226-3237. PubMed ID: 35322575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.